• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Therapeutic Areas
  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Cancer Drug Discovery

Advancing Cancer Drug Discovery with 3D Tissue Models


The Need for Predictive Models

Cancer causes over 10 million deaths annually, highlighting the critical need for new, effective treatments. Yet, the journey from lab to clinic faces a stark challenge: current models fall short in mirroring the complexity of human tumors, with only 5% of new cancer drugs reaching the market.

The solution is clear – adopting more predictive models that accurately reflect human biology. At MIMETAS, we offer you the most comprehensive, quantitative, and scalable platform to support you in your drug discovery journey.

Unlock Breakthrough Cancer Therapies with MIMETAS' Oncology Services

Using our OrganoCore® Discovery Platform, we capture the tumor microenvironment with unprecedented accuracy. Our 3D tumor models are tailored for each phase of the drug discovery process, delivering predictive insights that accelerate the development of targeted therapies. MIMETAS sets new precision oncology standards and redefines the boundaries of cancer research with our clients.


Speak With an Expert

Oncology Applications of 3D Tumor Models

T-cell Extravasation and Migration Towards Cancer Cells


Immune cell migration is crucial for immunotherapy success, especially in treating cancers like metastatic melanoma. MIMETAS' 3D endothelium-on-a-chip model revolutionizes the study of T-cell migration, offering deeper insights for advancing immunotherapy strategies against solid tumors.

 

App Note: T-Cell Transendothelial Migration

CAR T Cell Migration and Tumor Cell-Killing

Despite showing promising results in hematological malignancies, CAR T cell therapies have limited success in solid tumors. This is largely due to the complex tumor microenvironment (TME) of solid tumors. MIMETAS develops 3D solid tumor models that include factors such as immunosuppressive cells, soluble factors, and ECM stiffness. This enables the assessment of transmigration, recruitment and tumor cell killing by CAR T cells.

 

Webinar: Disease Modeling for Immuno-Oncology

Integrating Stroma and Macrophage Modulation

MIMETAS’ 3D tumor-on-chip model meticulously integrates cancer cells, stromal cells, tumor-associated macrophages (TAMs) and vasculature to mimic the dynamic TME of solid tumors. We provide a flexible and modular platform that enables the combination of different cell types in one and/or different compartments, providing critical insights into how stromal components and TAMs influence immune cell behavior and cancer progression.

 

Roundtable Discussion: Innovations in Cancer Therapies

Assessing Compounds in a 3D Hepatocellular Carcinoma (HCC) Model

 

HCC is notoriously difficult to treat due to its aggressive behavior, late diagnosis, and intricate tumor microenvironment. MIMETAS developed a screenable HCC-on-a-chip model using patient-derived material. This platform was used to test 28 different treatment conditions within a vascularized microenvironment with cancer-associated fibroblasts. This innovative model enables precise drug interaction studies, offering insights to overcome TME barriers and pave the way for optimized, patient-specific therapies against this formidable cancer.

 

Download the Poster

High-throughput Screening for Anti-angiogenetic Compounds

 

Angiogenesis plays a crucial role in cancer development and progression, making it a key target for cancer therapy. However, studying this in vitro can be difficult as most models have limited translatability and lack throughput. MIMETAS recently executed the first large scale organ-on-a-chip screen, screening over 1500 compounds in one go for anti-angiogenic potential and endothelial toxicity in a 3D angiogenesis assay.

 

Read our Angiogenesis Whitepaper

Read the publication

Modeling Chemotherapy-Induced Peripheral Neuropathy (CIPN)

 

CIPN is a debilitating side effect of cancer treatments like antibody drug conjugates (ADCs). Leveraging our 3D human motor and sensory models, we enable the precise study of neurotoxic effects and identifying safer ADCs. This improves patient care by mimicking human neuronal responses, offering a scalable, ethical alternative to animal testing.

 

Download the Poster

Want to explore these applications further? Download our latest whitepaper to uncover:

 

  • The urgent need for advanced, predictive models in cancer research.
  • Insights from six oncology applications of MIMETAS’ 3D tumor models.
  • Quantifiable results for informative decision making.
  • The impact of a strategic partnership with MIMETAS in accelerating the discovery of new cancer treatments.


 

Download the Whitepaper

Strategic Partnership in Immuno-Oncology

 

On March 28, 2023, MIMETAS and Astellas Pharma Inc., a global pharmaceutical company, entered a strategic partnership. This partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncology therapies. Under the partnership, Astellas will receive access to MIMETAS’ immuno-oncology disease assays. MIMETAS will be eligible for upfront and milestone payments.

 

Read the press release

Advancing Drug Discovery with MIMETAS

Are you interested in exploring potential partnership or service opportunities or learning more about our ongoing projects? Please contact us.


Contact us

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all